This scientific endeavor has been the focus goal of Dicerna Pharmaceuticals, a biopharmaceutical company dedicated to improving the lives of patients suffering from inherited diseases. The specialty of the company lies in understanding and creating novelty therapeutics for the diseases of the liver and those genetically defined cancers. Since the company’s inception in 2006 it has harnessed the potential of their RNA interference (RNAi) technology to create a pipeline of promising products.
Through its own research efforts and through collaborative studies, the company is able to create product candidates that would target and silence oncogene KRAS. The latter is a gene that mostly starts the formation of several cancers. Dicerna Pharmaceuticals is currently headquartered in Cambridge, Massachusetts.